Diagnosis & Symptoms
- Beyond bone fragility, symptoms can include short stature, joint laxity (loose joints), muscle weakness, blue or grey sclera (the whites of the eyes), hearing loss, brittle teeth (Dentinogenesis Imperfecta), and respiratory issues.
-
The “blue sclera” occurs because the collagen in the whites of the eyes is thinner than normal, allowing the underlying veins to show through. This is most common in Type I and Type III OI.
-
Diagnosis is typically made through a clinical evaluation by a specialist, which may include a physical exam, review of fracture history, and X-rays. Genetic testing or a skin biopsy to analyze collagen can confirm the diagnosis and identify the specific type.
-
No. OI is a physical condition involving connective tissue; it does not impact cognitive or intellectual development. Many individuals with OI pursue high-level education and successful careers.
Living with OI
-
In many cases, the frequency of fractures decreases significantly after puberty when bone growth slows down. However, women may see an increase in fractures after menopause, and men may also see an increase later in life due to age-related bone loss.
-
Approximately 50% of adults with OI experience some degree of hearing loss, often starting in their 20s or 30s. This is caused by the brittle bones in the middle ear not conducting sound properly or damage to the inner ear.
-
Most people with OI have a normal life expectancy. Individuals with very severe forms may face life-threatening respiratory or cardiac complications, but with modern medical management, most live long, productive lives.
Management & Treatment
-
Currently, there is no cure for OI. Management focuses on preventing and treating fractures, minimizing pain, and maximizing independent function and mobility.
-
Treatments often include “rodding” surgery (inserting metal rods into long bones for support), physical therapy to strengthen muscles and improve mobility, and the use of medications such as bisphosphonates to increase bone density and reduce fracture rates.
-
Rodding involves a surgeon placing a metal rod (sometimes an “extending” or “telescopic” rod) inside the marrow cavity of a long bone (like the femur or tibia). This helps to straighten deformities and provides internal support to prevent future breaks.
-
Yes, and it is highly encouraged. Physical activity helps build muscle strength, which supports the bones. Low-impact activities like swimming and water therapy are often ideal because they allow for movement without the stress of weight-bearing on the limbs.
-
Pain management is a critical part of care, as many adults and children experience both acute pain from fractures and chronic pain from joint laxity or spinal issues. Management may include physical therapy, specialized exercise, and consultation with a pain management specialist.
Support & Resources
-
The OI Society provides a community for those affected by the condition, offering information, peer support, and advocacy. They help connect families, provide updates on latest research, and raise awareness across Australia.
-
Yes. Many Australians living with OI access support through the NDIS. Funding can cover a range of needs including physiotherapy, occupational therapy, home and vehicle modifications, and assistive technology like wheelchairs or walkers.
-
Membership is open to individuals with OI, their families, and interested professionals. Annual fees are $20 for adults and $15 for children (aged 16 and under). Membership helps support the society’s work and provides access to community events and resources.
-
For more localised information and support, you can explore the resources available through the OI Society of Australia (oiaustralia.org.au), the OI Foundation (oif.org) for clinical facts, and the OI Federation Europe (oife.org) for international research and adult health initiatives.
Understanding Osteogenesis Imperfecta
-
Osteogenesis Imperfecta (OI), often referred to as “brittle bone disease,” is a rare genetic disorder characterized by bones that break easily, frequently from little or no apparent cause. It is caused by a defect in the body’s production of collagen, the protein that acts as the “scaffolding” for bones and other connective tissues.
-
Most cases (about 85–90%) are caused by a dominant mutation in the genes responsible for Type 1 collagen. This results in the body either producing too little collagen or producing collagen of poor quality. While it is often inherited from a parent, about 35% of children with OI are born into families with no prior history of the condition due to a spontaneous genetic mutation.
-
Professor David Sillence’s work, specifically his 1979 study “Genetic heterogeneity in osteogenesis imperfecta,” transformed the medical understanding of the condition from a single disease into a spectrum of distinct types. This framework, known as the Sillence Classification, remains the international standard for diagnosis.
Under his research, OI is categorized by clinical severity, physical features, and the way it is inherited.
The Four Primary Types (Original Sillence Classification)
-
Type I (Mild): The most common form. It is characterised by bone fragility, blue-tinted sclera (the whites of the eyes), and a high incidence of hearing loss in adulthood. In this type, the body produces normal-quality collagen but in insufficient quantities.
-
Type II (Perinatal Lethal): The most severe form, often identified during pregnancy or at birth. It involves extreme bone fragility, severe limb deformities, and respiratory failure.
-
Type III (Progressively Deforming): This type is characterised by severe bone fragility and a tendency for bones to curve over time, leading to significant physical disability. Sclera may be blue at birth but often turn white or grey as the person ages.
-
Type IV (Moderate): This group sits between Types I and III in terms of severity. A distinguishing feature identified by Professor Sillence is that individuals with Type IV typically have white or normal-colored sclera, even though they experience significant bone fragility and short stature.
The Evolution of Types (V and Beyond)
In his more recent work, Professor Sillence has acknowledged that as genetic research progressed, the classification expanded. While the original four types were based on phenotype (how the condition appears physically), researchers later identified types V through XX+ based on specific genotypes (the exact gene mutation involved).
-
Type V: Identified specifically by its unique bone structure (“mesh-like”) under a microscope and a tendency for large calluses to form where bones heal.
-
Molecular Typing: Professor Sillence now advocates for a “dyadic” approach, where a patient is given a clinical type (e.g., Type III) followed by their genetic mutation (e.g., COL1A1).
-
-
Not necessarily. While some individuals have visible physical characteristics like short stature or bone curvature, others with milder forms (Type I) may appear to have no outward signs of the condition, though they remain at higher risk for fractures and other internal complications.
